GlassScriptPhysician profile
Sara Haidar
NPI 1679956999
$3,585.47
in general payments reported to CMS, 2019-2025
20 companies · $2,896 in 2025
The $2,896 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $63.63 · 2021: $54.07 · 2022: $153 · 2023: $110 · 2024: $196 · 2025: $2,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $1,707 · Travel and Lodging: $904 · Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $1,706.86 |
| Travel and Lodging | $903.97 |
| Food and Beverage | $591.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,645.95 | 2025 | |
| Hologic Sales and Service, LLC | $206.15 | 2022-2025 | Acessa Provu System, Coolseal Generator |
| Aspira Women'S Health INC | $205.68 | 2019-2025 | Ova1 |
| Gynesonics, INC. | $148.64 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Sage Therapeutics, LLC | $67.11 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $57.37 | 2023-2024 | Myfembree |
| Abbvie INC. | $37.45 | 2019-2021 | |
| Boston Scientific Corporation | $29.38 | 2024 | |
| Evofem Biosciences, INC. | $20.39 | 2021 | |
| Myovant Sciences INC. | $19.77 | 2022 | |
| Fortovia Therapeutics, INC. | $18.30 | 2019 | |
| Dysis Medical, INC. | $17.83 | 2020 | |
| Astellas Pharma US INC | $17.37 | 2023 | Veozah |
| Supernus Pharmaceuticals, INC. | $15.61 | 2025 | Qelbree |
| Axonics, INC. | $15.04 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.97 | 2021 | |
| Lupin INC. | $13.14 | 2020 | |
| Shield Therapeutics INC | $12.91 | 2023 | Accrufer |
| Amgen INC. | $11.99 | 2019 | |
| Merck Sharp & Dohme LLC | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Haidar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.